Abbokinase® (urokinase) is a thrombolytic agent obtained from human neonatal kidney cells grown in tissue culture.
Abbokinase® is indicated in adults:
For the lysis of acute massive pulmonary emboli, defined as obstruction of blood flow to a lobe or multiple segments.
For the lysis of pulmonary emboli accompanied by unstable hemodynamics, i.e., failure to maintain blood pressure without supportive measures.
The diagnosis should be confirmed by objective means, such as pulmonary angiography or non-invasive procedures such as lung scanning.
Media Articles Related to Abbokinase (Urokinase)
Pulmonary Embolism (Blood Clot in the Lung)
Source: MedicineNet Chronic Cough Specialty [2015.02.27]
Title: Pulmonary Embolism (Blood Clot in the Lung)
Category: Diseases and Conditions
Created: 3/20/2008 12:00:00 AM
Last Editorial Review: 2/27/2015 12:00:00 AM
'Increased risk of venous thromboembolism among NSAID users'
Source: Body Aches News From Medical News Today [2014.09.25]
Venous thromboembolism - the condition that includes both deep vein thrombosis and pulmonary embolism - has been linked to NSAID use in a new systematic review and meta-analysis.
Published Studies Related to Abbokinase (Urokinase)
Pharmacokinetics and safety of a new bioengineered thrombolytic agent, human tissue urokinase type plasminogen activator in Chinese healthy volunteers. [2011.01]
The aim of our study was to investigate the pharmacokinetics and safety of human tissue urokinase type plasminogen activator (HTUPA) in healthy Chinese subjects after intravenous administration. Thirty-two subjects were given intravenous injection doses of 5-35 mg of HTUPA for safety evaluation... No serious adverse events were reported by the subjects or revealed by clinical or laboratory examinations, suggesting the given doses were safe and well tolerated.
An effective treatment for cerebral hemorrhage: minimally invasive craniopuncture combined with urokinase infusion therapy. [2010.05]
OBJECTIVES: To evaluate and compare the curative effect between the minimally invasive craniopuncture combined with urokinase infusion therapy and the clearance of hematoma by craniotomy with small bone flap in treating patients with 30-80 ml hemorrhage in the basal ganglion part of the brain... CONCLUSION: The craniopuncture combined with urokinase infusion therapy could reduce the rate of re-bleeding after surgery and the case fatality by 90 days. It also could improve the activities of daily living (Barthel index >or=95) at day 90. Thus, this therapy was a safe and practical technique in treating cerebral hemorrhage (30-80 ml), especially suitable for hospitals in rural areas or developing countries.
Efficacy and safety of 2-hour urokinase regime in acute pulmonary embolism: a randomized controlled trial. [2009.12.29]
BACKGROUNDS: Urokinase (UK) 2 200 U/kg.h for 12 hours infusion(UK-12 h)is an ACCP recommended regimen in treating acute pulmonary embolism (PE). It is unclear whether this dose and time can be reduced further. We compared the efficacy and safety of 20, 000 U/kg for 2 hours (UK-2 h) with the UK-12 h regime in selected PE patients... CONCLUSIONS: The UK-2 h regimen exhibits similar efficacy and safety as the UK-12 h regimen for acute PE.
[Thrombolysis of rabbit's pulmonary embolism with thrombus-targeted urokinase immune liposome] [2009.11]
OBJECTIVE: To develop thrombus-targeted urokinase immune liposome through incorporating D-dimer monoclonal antibody (DDmAb) to liposome and observe the thrombolytic efficiency in a rabbit pulmonary thromboembolism (PE) model... CONCLUSION: Acute PE could be successfully treated by the thrombus-targeted urokinase immune liposome with D-dimer monoclonal antibody.
Percutaneous treatment of intrabdominal abscess: urokinase versus saline serum in 100 cases using two surgical scoring systems in a randomized trial. [2009.07]
The purpose of this study was to assess whether regular instillation of urokinase during abscess drainage leads to an improved outcome compared to saline irrigation alone. One hundred patients referred for image-guided abdominal abscess drainage were randomized between thrice daily urokinase instillation or saline irrigation alone...
Clinical Trials Related to Abbokinase (Urokinase)
Safety and Efficacy Study of Urokinase for the Treatment of Diabetic Foot Syndrome and Critical Limb Ischemia [Recruiting]
In this randomized clinical trial (RCT) the investigators are trying to find out whether a
low-dose therapy with daily short infusions of urokinase using 10 to 21 doses over a maximum
of 30 days is capable of prolonging the survival time without major amputation.
Urokinase Therapy in Diabetic Foot Syndrome [Completed]
The purpose of this study is to evaluate whether a treatment with urokinase (500 000 or 1 000
000 IU) can lead to ulcer-healing, lower rate of major amputation, and prolonged survival in
patients with diabetic foot syndrome.
Urokinase Versus Video-Assisted Thoracoscopic to Treat Complicated Parapneumonic Empyema in Childhood [Recruiting]
A great controversy exists about which is the best method to perform the evacuation of the
collection. To evaluate which is the best initial treatment to drain complicated
parapneumonic empyema (stages II and III) in children: the present study raises a hypothesis
of equivalence between both arms of treatment (chest drainage plus intrapleural urokinase or
Urokinase Therapy in Patients With Diabetic Foot Syndrome [Recruiting]
The purpose of this study is to determine whether the additional therapy with low dose
urokinase is more effective than only a conventional standard therapy concerning
ulcer-healing, rate of major amputation and survival.